---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-168545"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:36:59.236867+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Intellia Therapeutics appoints Edward Dulac as CFO; Glenn Goddard steps down June 30, 2024

## Summary
- Edward Dulac appointed EVP, CFO, and Treasurer, effective July 22, 2024.
- Glenn Goddard steps down as CFO effective June 30, 2024; departure not related to any disagreement.
- Michael P. Dube (CAO) to serve as interim principal financial officer until Dulac's start date.
- Dulac receives $510K base salary, 40% target bonus, $100K sign-on bonus, and equity awards of ~$4.2M.
- Board approved 2024 Inducement Plan reserving 850,000 shares for new employee equity grants.

## SEC filing metadata
- accession: 0001193125-24-168545
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/0001193125-24-168545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/d822257d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-168545
- JSON: https://secwatch.observer/filing/0001193125-24-168545.json
- Plain text: https://secwatch.observer/filing/0001193125-24-168545.txt

## Key facts
- Executive change
  Michael P. Dube was appointed as interim principal financial officer at Intellia Therapeutics, Inc..
  - Action: appointed
  - Role: interim principal financial officer
  source text: Michael P. Dube, the Company’s Chief Accounting Officer, will serve as the Company’s interim principal financial officer until the Start Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/0001193125-24-168545-index.htm
- Executive change
  Edward Dulac was appointed as Executive Vice President and Chief Financial Officer at Intellia Therapeutics, Inc..
  - Action: appointed
  - Role: Executive Vice President and Chief Financial Officer
  source text: the Company announced the appointment, effective July 22, 2024 (“Start Date”), of Edward Dulac to serve as Executive Vice President and Chief Financial Officer (“CFO”), treasurer and principal financial officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/0001193125-24-168545-index.htm
- Executive change
  Glenn Goddard departed as Chief Financial Officer at Intellia Therapeutics, Inc..
  - Action: stepped down
  - Role: Chief Financial Officer
  source text: the Company also announced that Glenn Goddard, the Company’s current CFO, will step down effective June 30, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/0001193125-24-168545-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.